Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models.
Li Y, Amaladas N, O'Mahony M, Manro JR, Inigo I, Li Q, Rasmussen ER, Brahmachary M, Doman TN, Hall G, Kalos M, Novosiadly R, Puig O, Pytowski B, Schaer DA. Li Y, et al. Among authors: hall g. PLoS One. 2022 Jul 18;17(7):e0268244. doi: 10.1371/journal.pone.0268244. eCollection 2022. PLoS One. 2022. PMID: 35849586 Free PMC article.
Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.
Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M. Li Y, et al. Among authors: hall g. J Immunother Cancer. 2018 Apr 30;6(1):31. doi: 10.1186/s40425-018-0329-7. J Immunother Cancer. 2018. PMID: 29712568 Free PMC article.
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE. Holmgaard RB, et al. J Immunother Cancer. 2018 Jun 4;6(1):47. doi: 10.1186/s40425-018-0356-4. J Immunother Cancer. 2018. PMID: 29866156 Free PMC article.
Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054.
Li Y, Carpenito C, Wang G, Surguladze D, Forest A, Malabunga M, Murphy M, Zhang Y, Sonyi A, Chin D, Burtrum D, Inigo I, Pennello A, Shen L, Malherbe L, Chen X, Hall G, Haidar JN, Ludwig DL, Novosiadly RD, Kalos M. Li Y, et al. Among authors: hall g. J Immunother Cancer. 2018 Jun 4;6(1):45. doi: 10.1186/s40425-018-0354-6. J Immunother Cancer. 2018. PMID: 29866166 Free PMC article.
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
Schaer DA, Geeganage S, Amaladas N, Lu ZH, Rasmussen ER, Sonyi A, Chin D, Capen A, Li Y, Meyer CM, Jones BD, Huang X, Luo S, Carpenito C, Roth KD, Nikolayev A, Tan B, Brahmachary M, Chodavarapu K, Dorsey FC, Manro JR, Doman TN, Donoho GP, Surguladze D, Hall GE, Kalos M, Novosiadly RD. Schaer DA, et al. Clin Cancer Res. 2019 Dec 1;25(23):7175-7188. doi: 10.1158/1078-0432.CCR-19-0433. Epub 2019 Aug 13. Clin Cancer Res. 2019. PMID: 31409612
Portable Acceleration of CMS Computing Workflows with Coprocessors as a Service.
CMS Collaboration; Hayrapetyan A, Tumasyan A, Adam W, Andrejkovic JW, Bergauer T, Chatterjee S, Damanakis K, Dragicevic M, Hussain PS, Jeitler M, Krammer N, Li A, Liko D, Mikulec I, Schieck J, Schöfbeck R, Schwarz D, Sonawane M, Templ S, Waltenberger W, Wulz CE, Darwish MR, Janssen T, Mechelen PV, Bols ES, D'Hondt J, Dansana S, De Moor A, Delcourt M, Faham HE, Lowette S, Makarenko I, Müller D, Sahasransu AR, Tavernier S, Tytgat M, Onsem GPV, Putte SV, Vannerom D, Clerbaux B, Das AK, De Lentdecker G, Favart L, Gianneios P, Hohov D, Jaramillo J, Khalilzadeh A, Khan FA, Lee K, Mahdavikhorrami M, Malara A, Paredes S, Thomas L, Bemden MV, Velde CV, Vanlaer P, De Coen M, Dobur D, Hong Y, Knolle J, Lambrecht L, Mestdach G, Amarilo KM, Rendón C, Samalan A, Skovpen K, Bossche NVD, Linden JV, Wezenbeek L, Benecke A, Bethani A, Bruno G, Caputo C, Delaere C, Donertas IS, Giammanco A, Jaffel K, Jain S, Lemaitre V, Lidrych J, Mastrapasqua P, Mondal K, Tran TT, Wertz S, Alves GA, Coelho E, Hensel C, De Oliveira TM, Moraes A, Teles PR, Soeiro M, Júnior WLA, Pereira MAG, Filho MBF, Malbouisson HB, Carvalho W, Chinellato J, Da Costa EM, Da Silveira GG, De Jesus Damiao D, De Souza SF, De Souza RG, M… See abstract for full author list ➔ CMS Collaboration, et al. Among authors: hall g. Comput Softw Big Sci. 2024;8(1):17. doi: 10.1007/s41781-024-00124-1. Epub 2024 Sep 4. Comput Softw Big Sci. 2024. PMID: 39248308 Free PMC article.
A prospective multicenter observational study assessing incidence and risk factors for acute blood transfusion reactions in dogs.
Hall GBF, Birkbeck R, Brainard BM, Camacho F, Davidow EB, LeVine DN, Mackin A, Moss T, Nash KJ, Stanzani G, Starybrat D, Stoye DQ, Tai C, Thomason J, Walker JM, Wardrop KJ, Wilson H, Wurlod VA, Humm K. Hall GBF, et al. J Vet Intern Med. 2024 Sep 6. doi: 10.1111/jvim.17175. Online ahead of print. J Vet Intern Med. 2024. PMID: 39239720 Free article.
Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer.
Xu-Vuillard A, Guerin-Charbonnel C, Bocquet F, Cheeseman S, Kubelac PM, Zenatri M, Hall G, Achimas-Cadariu P, Hanvic B, Fenton H, Sturz-Lazăr AM, Augereau P, Coquard IR, Leary A, Frenel JS. Xu-Vuillard A, et al. Among authors: hall g. ESMO Open. 2024 Sep 3;9(9):103694. doi: 10.1016/j.esmoop.2024.103694. Online ahead of print. ESMO Open. 2024. PMID: 39232440 Free PMC article.
3,152 results